Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ

References

• Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596–601.
   PubMed Web of Science ®Google Scholar
• Neal B, Chapman N, Patel A. Managing the global burden of cardiovascular disease. Eur Heart J Suppl 2002;4:F2–6
   Web of Science ®Google Scholar
• Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003;139:761–76.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004;17:1192–200.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7–13.
   PubMed Web of Science ®Google Scholar
• Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002;2:126–30.
   PubMed Web of Science ®Google Scholar
• Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 2008;26:269–75.
   PubMed Web of Science ®Google Scholar
• Takase H, Kimura G, Dohi Y. Uric acid levels predict future blood pressure and new onset hypertension in the general Japanese population. J Hum Hypertens 2014;16:143.
   Google Scholar
• Anzai N, Enomoto A, Endou H. Renal urate handling: clinical relevance of recent advances. Curr Rheumatol Rep 2005;7:227–34.
   PubMedGoogle Scholar
• Kanbay M, Solak Y, Dogan E, et al. Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif 2010;30:288–95.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Sautin YY, Oliver WJ, et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B Biochem Syst Environ Physiol 2009;179:67–76.
   PubMed Web of Science ®Google Scholar
• Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287–93.
   PubMed Web of Science ®Google Scholar
• Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991;266:8604–8.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991–7.
   PubMed Web of Science ®Google Scholar
• So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010;120:1791–9.
   PubMed Web of Science ®Google Scholar
• Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005;25:425–33.
   PubMed Web of Science ®Google Scholar
• Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol: JASN 2006;17:1791–5.
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888–97.
   PubMed Web of Science ®Google Scholar
• Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J 2006;27:1174–81.
   PubMed Web of Science ®Google Scholar
• Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 2007;17:409–14.
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739–42.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Maio R, Mallamaci F, et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006;17:1466–71.
   PubMed Web of Science ®Google Scholar
• Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619–24.
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000;93:65–77.
   PubMed Web of Science ®Google Scholar
• Shen YJ, Zhu XX, Yang X, et al. Cardamonin inhibits angiotensin II-induced vascular smooth muscle cell proliferation and migration by downregulating p38 MAPK, Akt, and ERK phosphorylation. J Nat Med 2014;68:623–9.
   PubMed Web of Science ®Google Scholar
• Viedt C, Soto U, Krieger-Brauer HI, et al. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 2000;20:940–8.
   PubMed Web of Science ®Google Scholar
• Won SM, Park YH, Kim HJ, et al. Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med 2006;38:525–34.
   PubMed Web of Science ®Google Scholar
• Saito Y, Berk BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 2001;33:3–7.
   PubMed Web of Science ®Google Scholar
• Kim S, Zhan Y, Izumi Y, et al. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 2000;20:2539–45.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Nakagawa T, Kang DH, et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 2006;15:30–3.
   PubMed Web of Science ®Google Scholar
• Cetin A, Ozturk OH, Tokay A, et al. Angiotensin II-induced MAPK phosphorylation mediated by Ras and/or phospholipase C-dependent phosphorylations but not by protein kinase C phosphorylation in cultured rat vascular smooth muscle cells. Pharmacology 2007;79:27–33.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101–6.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2–7.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283:F1105–10.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355–60.
   PubMed Web of Science ®Google Scholar
• Gaffo AL, Edwards NL, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther 2009;11:240.
   PubMed Web of Science ®Google Scholar
• Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthrit Rheum 2009;61:885–92.
   PubMed Web of Science ®Google Scholar
• Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol: JASN 2005;16:3553–62.
   PubMed Web of Science ®Google Scholar
• Fauvel JP, Velon S, Berra N, et al. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996;28:259–63.
   PubMed Web of Science ®Google Scholar
• Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008;21:1157–62.
   PubMed Web of Science ®Google Scholar
• Sato M, Iwanaga T, Mamada H, et al. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 2008;25:639–46.
   PubMed Web of Science ®Google Scholar
• Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens (New York, NY : 1993). 2015;37(3):192–6. Epub 2014/07/23.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Anzai N, Jutabha P, et al. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci 2010;114:115–18.
   PubMed Web of Science ®Google Scholar
• Albertoni G, Maquigussa E, Pessoa E, et al. Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp Biol Med (Maywood) 2010;235:825–32.
   PubMed Web of Science ®Google Scholar